Cargando…

High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study

INTRODUCTION: Aiming to reach UNAIDS 90‐90‐90 targets, nearly all sub‐Saharan African countries have expanded antiretroviral therapy (ART) to all people living with HIV (PLWH) (Treat All). Few published data exist on viral load testing and viral suppression under Treat All in this region. We assesse...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Jonathan, Ribakare, Muhayimpundu, Remera, Eric, Murenzi, Gad, Munyaneza, Athanase, Hoover, Donald R, Shi, Qiuhu, Nsanzimana, Sabin, Yotebieng, Marcel, Nash, Denis, Anastos, Kathryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293767/
https://www.ncbi.nlm.nih.gov/pubmed/32536033
http://dx.doi.org/10.1002/jia2.25543
_version_ 1783546356889026560
author Ross, Jonathan
Ribakare, Muhayimpundu
Remera, Eric
Murenzi, Gad
Munyaneza, Athanase
Hoover, Donald R
Shi, Qiuhu
Nsanzimana, Sabin
Yotebieng, Marcel
Nash, Denis
Anastos, Kathryn
author_facet Ross, Jonathan
Ribakare, Muhayimpundu
Remera, Eric
Murenzi, Gad
Munyaneza, Athanase
Hoover, Donald R
Shi, Qiuhu
Nsanzimana, Sabin
Yotebieng, Marcel
Nash, Denis
Anastos, Kathryn
author_sort Ross, Jonathan
collection PubMed
description INTRODUCTION: Aiming to reach UNAIDS 90‐90‐90 targets, nearly all sub‐Saharan African countries have expanded antiretroviral therapy (ART) to all people living with HIV (PLWH) (Treat All). Few published data exist on viral load testing and viral suppression under Treat All in this region. We assessed proportions of patients with available viral load test results and who were virally suppressed, as well as factors associated with viral suppression, among PLWH in 10 Rwandan health centres after Treat All implementation. METHODS: Cross‐sectional study during 2018 of adults (≥15 years) engaged in HIV care at 10 Rwandan health centres. Outcomes were being on ART (available ART initiation date in the study database, with no ART discontinuation prior to 1 January 2018), retained on ART (≥2 post‐ART health centre visits ≥90 days apart during 2018), available viral load test results (viral load measured in 2018 and available in study database) and virally suppressed (most recent 2018 viral load <200 copies/mL). We used modified Poisson regression models accounting for clustering by health centre to determine factors associated with being virally suppressed. RESULTS: Of 12,238 patients, 7050 (58%) were female and 1028 (8%) were aged 15 to 24 years. Nearly all patients (11,933; 97%) were on ART, of whom 11,198 (94%) were retained on ART. Among patients retained on ART, 10,200 (91%) had available viral load results; of these 9331 (91%) were virally suppressed. Viral suppression was less likely among patients aged 15 to 24 compared to >49 years (adjusted prevalence ratio (aPR): 0.83, 95% CI 0.76 to 0.90 and those with pre‐ART CD4 counts of <200 compared to ≥500 cells/mm(3) (aPR: 0.92, 95% CI 0.90 to 0.93). There was no statistically significant difference in viral suppression among patients who entered after Treat All implementation compared to those who enrolled before 2010 (aPR 0.98, 95% CI 0.94 to 1.03). CONCLUSIONS: In this large cohort of Rwandan PLWH receiving HIV care after Treat All implementation, patients in study health centres have surpassed the third UNAIDS 90‐90‐90 target. To ensure all PLWH fully benefit from ART, additional efforts should focus on improving ART adherence among younger persons.
format Online
Article
Text
id pubmed-7293767
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72937672020-06-15 High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study Ross, Jonathan Ribakare, Muhayimpundu Remera, Eric Murenzi, Gad Munyaneza, Athanase Hoover, Donald R Shi, Qiuhu Nsanzimana, Sabin Yotebieng, Marcel Nash, Denis Anastos, Kathryn J Int AIDS Soc Short Reports INTRODUCTION: Aiming to reach UNAIDS 90‐90‐90 targets, nearly all sub‐Saharan African countries have expanded antiretroviral therapy (ART) to all people living with HIV (PLWH) (Treat All). Few published data exist on viral load testing and viral suppression under Treat All in this region. We assessed proportions of patients with available viral load test results and who were virally suppressed, as well as factors associated with viral suppression, among PLWH in 10 Rwandan health centres after Treat All implementation. METHODS: Cross‐sectional study during 2018 of adults (≥15 years) engaged in HIV care at 10 Rwandan health centres. Outcomes were being on ART (available ART initiation date in the study database, with no ART discontinuation prior to 1 January 2018), retained on ART (≥2 post‐ART health centre visits ≥90 days apart during 2018), available viral load test results (viral load measured in 2018 and available in study database) and virally suppressed (most recent 2018 viral load <200 copies/mL). We used modified Poisson regression models accounting for clustering by health centre to determine factors associated with being virally suppressed. RESULTS: Of 12,238 patients, 7050 (58%) were female and 1028 (8%) were aged 15 to 24 years. Nearly all patients (11,933; 97%) were on ART, of whom 11,198 (94%) were retained on ART. Among patients retained on ART, 10,200 (91%) had available viral load results; of these 9331 (91%) were virally suppressed. Viral suppression was less likely among patients aged 15 to 24 compared to >49 years (adjusted prevalence ratio (aPR): 0.83, 95% CI 0.76 to 0.90 and those with pre‐ART CD4 counts of <200 compared to ≥500 cells/mm(3) (aPR: 0.92, 95% CI 0.90 to 0.93). There was no statistically significant difference in viral suppression among patients who entered after Treat All implementation compared to those who enrolled before 2010 (aPR 0.98, 95% CI 0.94 to 1.03). CONCLUSIONS: In this large cohort of Rwandan PLWH receiving HIV care after Treat All implementation, patients in study health centres have surpassed the third UNAIDS 90‐90‐90 target. To ensure all PLWH fully benefit from ART, additional efforts should focus on improving ART adherence among younger persons. John Wiley and Sons Inc. 2020-06-14 /pmc/articles/PMC7293767/ /pubmed/32536033 http://dx.doi.org/10.1002/jia2.25543 Text en © 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Ross, Jonathan
Ribakare, Muhayimpundu
Remera, Eric
Murenzi, Gad
Munyaneza, Athanase
Hoover, Donald R
Shi, Qiuhu
Nsanzimana, Sabin
Yotebieng, Marcel
Nash, Denis
Anastos, Kathryn
High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title_full High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title_fullStr High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title_full_unstemmed High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title_short High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study
title_sort high levels of viral load monitoring and viral suppression under treat all in rwanda – a cross‐sectional study
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293767/
https://www.ncbi.nlm.nih.gov/pubmed/32536033
http://dx.doi.org/10.1002/jia2.25543
work_keys_str_mv AT rossjonathan highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT ribakaremuhayimpundu highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT remeraeric highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT murenzigad highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT munyanezaathanase highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT hooverdonaldr highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT shiqiuhu highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT nsanzimanasabin highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT yotebiengmarcel highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT nashdenis highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT anastoskathryn highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy
AT highlevelsofviralloadmonitoringandviralsuppressionundertreatallinrwandaacrosssectionalstudy